Krężel Piotr, Olejniczak Teresa, Tołoczko Aleksandra, Gach Joanna, Weselski Marek, Bronisz Robert
Faculty of Biotechnology and Food Science, Wrocław University of Environmental and Life Sciences, Norwida 25, 50-375 Wrocław, Poland.
Faculty of Chemistry, University of Wrocław, F. Joliot-Curie 14, 50-383 Wrocław, Poland.
Antibiotics (Basel). 2022 Oct 28;11(11):1500. doi: 10.3390/antibiotics11111500.
The resistance of and other pathogenic yeasts to azole antifungal drugs has increased rapidly in recent years and is a significant problem in clinical therapy. The current state of pharmacological knowledge precludes the withdrawal of azole drugs, as no other active substances have yet been developed that could effectively replace them. Therefore, one of the anti-yeast strategies may be therapies that can rely on the synergistic action of natural compounds and azoles, limiting the use of azole drugs against candidiasis. Synergy assays performed in vitro were used to assess drug interactions Fractional Inhibitory Concentration Index. The synergistic effect of fluconazole () and three synthetic lactones identical to those naturally occurring in celery plants-3--butylphthalide (), 3--butylidenephthalide (), 3--butyl-4,5,6,7-tetrahydrophthalide ()-against ATCC 10231, ATCC 2091, and KKP 3390 was compared with the performance of the individual compounds separately. MIC (the amount of fungistatic substance (in µg/mL) inhibiting yeast growth by 90%) was determined as 5.96-6.25 µg/mL for fluconazole () and 92-150 µg/mL for lactones With the simultaneous administration of fluconazole () and one of the lactones , it was found that they act synergistically, and to achieve the same effect it is sufficient to use 0.58-6.73 µg/mL fluconazole () and 1.26-20.18 µg/mL of lactones . As fluconazole and phthalide lactones show synergy, 11 new fluconazole analogues with lower toxicity and lower inhibitory activity for CYP2C19, CYP1A2, and CYP2C9, were designed after in silico testing. The lipophilicity was also analyzed. A three-carbon alcohol with two rings was preserved. In all compounds 5-15, the 1,2,4-triazole rings were replaced with 1,2,3-triazole or tetrazole rings. The hydroxyl group was free or esterified with phenylacetic acid or thiophene-2-carboxylic acid chlorides or with adipic acid. In structures and the hydroxyl group was replaced with the fragment -CHCl or = CH. Additionally, the difluorophenyl ring was replaced with unsubstituted phenyl. The structures of the obtained compounds were determined by H NMR, and C NMR spectroscopy. Molecular masses were established by GC-MS or elemental analysis. The MIC and MIC of all compounds were determined against ATCC 10231, ATCC 2091, AM 38/20, KKP 3390, and KKP 3528. The MIC values for the newly prepared compounds ranged from 38.45 to 260.81 µg/mL. The 90% inhibitory dose was at least twice as high. Large differences in the effect of fluconazole analogues on individual strains were observed. A synergistic effect on three strains- ATCC 10231, ATCC 2091, KKP 339-was observed. Fractional inhibitory concentrations FIC and FIC were tested for the most active lactone, 3--butylphthalide, and seven fluconazole analogues. The strongest synergistic effect was observed for the strain ATCC 10231, FIC 0.04-0.48. The growth inhibitory amount of azole is from 25 to 55 µg/mL and from 3.13 to 25.3 µg/mL for 3--butylphthalide. Based on biological research, the influence of the structure on the fungistatic activity and the synergistic effect were determined.
近年来,白色念珠菌和其他致病性酵母菌对唑类抗真菌药物的耐药性迅速增加,这在临床治疗中是一个重大问题。目前的药理学知识状况使得唑类药物无法停用,因为尚未开发出其他能够有效替代它们的活性物质。因此,抗酵母菌策略之一可能是依赖天然化合物与唑类协同作用的疗法,从而限制唑类药物用于治疗念珠菌病。体外进行的协同试验用于评估药物相互作用的分数抑制浓度指数。将氟康唑()与三种与芹菜植物中天然存在的内酯相同的合成内酯——3 - 正丁基苯酞()、3 - 亚丁基苯酞()、3 - 正丁基 - 4,5,6,7 - 四氢苯酞()——对白色念珠菌ATCC 10231、热带念珠菌ATCC 2091和光滑念珠菌KKP 3390的协同作用与单独使用各化合物的效果进行了比较。氟康唑()的MIC(抑制酵母菌生长90%的抑菌物质的量(以μg/mL计))测定为5.96 - 6.25 μg/mL,内酯的MIC为92 - 150 μg/mL。同时给予氟康唑()和其中一种内酯时,发现它们具有协同作用,并且使用0.58 - 6.73 μg/mL氟康唑()和1.26 - 20.18 μg/mL内酯就足以达到相同效果。由于氟康唑和苯酞内酯显示出协同作用,在计算机模拟测试后设计了11种对CYP2C19、CYP1A2和CYP2C9毒性较低且抑制活性较低的新型氟康唑类似物。还分析了亲脂性。保留了带有两个环的三碳醇。在所有化合物5 - 15中,1,2,4 - 三唑环被1,2,3 - 三唑或四唑环取代。羟基是游离的,或者与苯乙酸、噻吩 - 2 - 羧酸氯或己二酸酯化。在结构和中,羟基被片段 -CHCl或 = CH取代。此外,二氟苯基环被未取代的苯基取代。通过1H NMR和13C NMR光谱测定所获得化合物的结构。通过GC - MS或元素分析确定分子量。测定了所有化合物对白色念珠菌ATCC 10231、热带念珠菌ATCC 2091、AM 38/20、光滑念珠菌KKP 3390和近平滑念珠菌KKP 3528的MIC和MFC。新制备化合物的MIC值范围为38.45至260.81 μg/mL。90%抑制剂量至少高两倍。观察到氟康唑类似物对各个菌株的作用存在很大差异。观察到对三种菌株——白色念珠菌ATCC 10231、热带念珠菌ATCC 2091、光滑念珠菌KKP 339——有协同作用。对活性最强的内酯3 - 正丁基苯酞和七种氟康唑类似物测试了分数抑制浓度FIC和FIC。在白色念珠菌ATCC 10231菌株中观察到最强的协同作用,FIC为0.04 - 0.48。唑类的生长抑制量为25至55 μg/mL,3 - 正丁基苯酞的生长抑制量为3.13至25.3 μg/mL。基于生物学研究,确定了结构对抑菌活性和协同作用的影响。